A new Human Pathology Atlas launched this month by researchers at Sweden’s national Science for Life Laboratory analyses all human genes in all major cancers, showing the consequence of their corresponding protein levels for overall patient survival
One stumbling block to personalised medicine is the upfront investment. Research for Science|Business is published in a peer-reviewed journal quantifying potential savings from a tailored programme of exercise, diagnostics and telemonitoring for heart care.
Index Ventures raised $400 million dollars in its last fund, of which about half will be invested in life science start-ups. Senior partner, Francesco de Rubertis says personalised medicine will take a large share of this.